Shineco Stock Price, News & Analysis

Shineco (NASDAQ: SISI) announced that its subsidiary InfiniClone, in which it holds a 51% stake, has entered into a strategic distribution agreement with Total World Marketing (TWM) to expand into Southeast Asia's healthcare market. InfiniClone will offer two main product lines: molecular detection kits based on iPSC technology for analyzing genetic mutations and diseases, and Purelix health products for customized immune enhancement and health solutions. TWM has begun pilot sales of Purelix products in Thai supermarkets and plans to expand to pharmacies, clinics, and e-commerce platforms once FDA approval is obtained for the molecular detection kits. The Southeast Asian healthcare market shows strong growth potential, with e-commerce platforms Shopee and Lazada reporting $1.57 billion in healthcare product sales in 2023, marking a 25% year-over-year increase.

Shineco (NASDAQ: SISI) has announced the acquisition of a 51% stake in InfiniClone , a Hong Kong-based biotechnology company specializing in regenerative medicine and stem cell technology. The transaction, valued at $19,895,600 in cash plus 3,450,000 shares of Shineco common stock, was executed through Shineco's subsidiary, Shineco Life Sciences.

InfiniClone possesses 29 global patents across major markets including the US, Europe, and Asia. Their innovative technology claims to increase cell expansion throughput by 3-10x compared to existing methods and reduce production costs by over 60%. The company's proprietary methods could potentially reduce treatment preparation time for conditions like Parkinson's, Alzheimer's, and stroke from months to weeks.

The acquisition marks Shineco's strategic entry into stem cell technology and regenerative medicine, with the company aiming to accelerate InfiniClone's technology transition from laboratory to clinical applications.

Shineco (NASDAQ: SISI) has announced the acquisition of a 75% equity stake in FuWang Company, a specialist in medical device R&D, manufacturing, and commercialization. The deal, signed on March 20, 2025, involves a payment of US$8.8 million in cash, issuance of 3,400,000 Shineco common shares, and transfer of 71.42% equity in Dream Partner

FuWang Company develops Class II and III medical devices, including biochemical analyzers, patient monitors, and mobile medical imaging workstations. The company has a strong market presence across Chinese provinces, particularly in Gansu, Henan, Jiangsu, and Shanxi.

The acquisition target projects revenue growth from US$11.03 million in 2025 to US$17.24 million by 2027, with net profit expectations ranging from US$1.10 million to US$1.72 million during the same period. FuWang plans to expand into integrated health management, leveraging cloud computing and AI technologies for critical care networks.

Shineco announced a 1-for-24 reverse stock split effective November 12, 2024, primarily to maintain Nasdaq Capital Market listing compliance by meeting minimum average closing share price requirements. The company's common stock will continue trading under SISI but with a new CUSIP Number (824567507). Following the split, outstanding shares will be reduced to 1,613,898. The split affects all issued shares, stock options, and warrants, with fractional shares rounded up. No stockholder action is required, and positions will be automatically adjusted through brokers.

Future FinTech Group Inc. (NASDAQ: FTFT) has announced a significant leadership change. Hu Li has been appointed as the new Chief Executive Officer, President, and Board member, effective August 5, 2024. Li replaces Shanchun Huang, who resigned for personal reasons. With a background in financial services and corporate management, Li brings valuable experience to FTFT's strategic transformation.

Li has been with FTFT since 2019, serving as Corporate Secretary and CEO of a subsidiary. He holds an MBA and has experience in public companies. The Board Chairman, Foyou Li, expressed confidence in Hu Li's ability to lead the company to new heights. Li himself committed to accelerating FTFT's global strategic growth plan and achieving sustainable development.

Shineco, Inc. (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, has closed its underwritten public offering of 1,869,160 shares of common stock at $1.07 per share. The offering raised approximately $2 million in gross proceeds, before deducting underwriting discounts and other expenses. EF Hutton acted as the sole book-running manager for the offering.

The company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares at the public offering price, less underwriting discounts. The offering was made pursuant to an effective shelf registration statement and accompanying prospectus filed with the SEC.

Shineco announced the pricing of its underwritten public offering of 1,869,160 shares of common stock at $1.07 per share, aiming to raise approximately $2 million before underwriting discounts and expenses. The offering includes a 45-day option for underwriters to purchase up to an additional 280,374 shares to cover over-allotments. The closing is expected on July 15, 2024, subject to customary conditions. EF Hutton is the sole book-running manager. The shares are offered under an effective shelf registration statement filed with the SEC. This press release is not an offer to sell or solicit the purchase of these securities.

Shineco (NASDAQ: SISI), a provider of innovative diagnostic medical products, announced an underwritten public offering of common stock and pre-funded warrants. All securities are offered by the Company, and the offering's completion is subject to market conditions. EF Hutton is the sole book-running manager. This offering is based on a previously filed and effective registration statement with the SEC. A preliminary prospectus supplement has been or will be filed with the SEC. Investors should refer to these documents for comprehensive details.

Shineco announced its subsidiary, Fuzhou Meida Health Management, has entered into distribution agreements for its water-soluble phospholipid concentrate health food beverage, projected to generate over $30 million in sales over three years.

The company highlights its advanced production technology, which ensures a pure physical separation and extraction of phospholipids without chemical solvents, providing a competitive edge.

Shineco has begun mass production to meet expected demand, aiming to diversify revenue streams within the healthcare sector. The global phospholipids market is predicted to grow significantly, presenting further opportunities.